|Baxter Launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System|
|View printer-friendly version|
“Healthcare leaders today are required to deliver clinical and financial
return on every dollar spent,” said
In place of the cost and labor associated with purchasing and installing external radio frequency identification (RFID) tags, DeviceVue receives a signal from the pump’s wireless radio that provides location data, whether the pump is in use, and the status of the pump battery, wireless network connection, and drug library. This data is sent in near real-time to the DeviceVue PC or mobile application.
DeviceVue is currently in use at multiple health systems across the
In addition to asset tracking, DeviceVue’s utilization reporting can help hospitals reduce costs by ensuring as many pumps as possible are put to use, while the ability to search for specific pumps by serial number can help biomedical engineers dramatically reduce the amount of time required to perform preventive maintenance.
For more information on the Sigma Spectrum Infusion System, please visit www.sigmapumps.com.
About Sigma Spectrum Infusion System
Sigma Spectrum’s hardware works in concert with the pump’s
software to encourage use of innovative features that are designed to
help enhance patient safety and clinician efficiency. For example, the
pumps automatically default to the installed drug library without
requiring clinicians to take extra steps to “opt-in,” and drug library
updates can be delivered wirelessly to pumps in the facility without
interrupting clinical workflow. Sigma Spectrum is the only pump
to include a built-in Dose/Rate Change Error Prevention Feature, which
helps clinicians protect high-risk infusions during titrations, and
allows pharmacists to customize dose change limits for individual drugs.
Sigma Spectrum also includes features like: integration with
electronic health record (EHR) systems—including
DeviceVue will work with any V8 and V6 Sigma Spectrum infusion
pump that has a wireless radio and
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's
DeviceVue and Sigma Spectrum Infusion System and related performance
data, including anticipated benefits associated with their use. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: satisfaction of
regulatory and other requirements; actions of regulatory bodies and
other governmental authorities; demand for and market acceptance of new
and existing products; product development risks; the impact of
competitive products and pricing; product quality, manufacturing or
supply issues; patient safety issues; breaches or failures of the
company’s information technology systems; changes in law and
regulations; and other risks identified in Baxter's most recent filing
on Form 10-K and other
Baxter and Sigma Spectrum are trademarks of
iPad and iPhone are registered trademarks of
The Magnet Recognition Program®, ANCC Magnet Recognition®, Magnet®, ANCC National Magnet Conference®, and Journey to Magnet Excellence® names and logos are registered trademarks of the American Nurses Credentialing Center. All rights reserved.
Epic is a registered trademark of
1 Data on File.
Baxter International Inc.